Industrial metals continue momentum as investors cheer another better-than-expected inflation report in the US
The unskilled workforce in particular will be affected by the steps the country will be compelled to take
Some of the employees of the arms manufacturer have not been paid for more than two years
The premier announced her cabinet after a meeting with the ANC’s deployment committee and its alliance partners
The Walt Disney business bets on ad-free viewing as it hikes premiums
Stats SA says ongoing power cuts limited recovery in the sector and reduced production volumes
The improved sentiment is a result of increased merchandise export and import volumes and more new vehicles sold, Sacci report says
Soldiers say they killed scores of attackers during hours-long bombardment that included drones, car bombs and artillery in southern Mali
Top swimmers have a rivalry that could develop into one of SA sport’s greatestt
The Italian SUV outguns the Bentley Bentayga's record
London — British and American pharmaceutical giants AstraZeneca and Eli Lilly said on Tuesday that they were ending a large clinical trial of a treatment for Alzheimer’s that they had been developing together.
The decision to scrap the phase III clinical trial is a major setback in the race to find a cure for the disease, which is the most common form of dementia affecting millions of people around the world.
"We are saddened by this outcome as our researchers are working tirelessly to find a solution for the many people who are impacted by this devastating disease," Menelas Pangalos, executive vice-president of AstraZeneca said in a statement.
"We won’t give up on finding a solution for Alzheimer’s patients," Daniel Skovronsky, president of Lilly Research Labs added.
The two firms had announced a partnership to develop a new drug aimed at combating Alzheimer’s in 2014. They were working on two treatments, one for patients of early Alzheimer’s disease, the other for those with mild ...
A subscription helps you enjoy the best of our business content every day along with benefits such as articles from our international business news partners; ProfileData financial data; and digital access to the Sunday Times and Sunday Times Daily.
Already subscribed? Simply sign in below.
Questions or problems? Email email@example.com or call 0860 52 52 00. Got a subscription voucher? Redeem it now
Would you like to comment on this article? Register (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.